GlassScriptPhysician profile
Erik R Kyler
NPI 1770745614
$5,707.96
in general payments reported to CMS, 2019-2025
19 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $184 · 2021: $337 · 2022: $607 · 2023: $2,077 · 2024: $1,935 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,951 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Travel and Lodging: $895 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.47 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Travel and Lodging | $894.70 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $3,338.89 | 2020-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $740.68 | 2019-2025 | Total30, Dailies Total1, Tryptyr |
| Johnson & Johnson Vision Care, INC. | $424.05 | 2022-2025 | Acuvue |
| Horizon Therapeutics Plc | $213.24 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $211.40 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $184.39 | 2023 | Miebo, Infuse, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $169.55 | 2024-2025 | Xdemvy |
| Allergan, INC. | $80.28 | 2021 | |
| Biotissue Holdings INC. | $72.04 | 2022-2025 | |
| Quidel Corporation | $49.98 | 2022 | |
| Maculogix, INC. | $45.74 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $44.12 | 2022 | |
| Dompe US, INC. | $23.16 | 2024 | Oxervate |
| Oyster Point Pharma, INC. | $20.68 | 2022 | |
| Kala Pharmaceuticals, INC. | $20.13 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $19.61 | 2024 | Clarus |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.69 | 2020 | |
| Abbvie INC. | $16.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Kyler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.